Machine learning-guided cell-free engineering creates specialized amide synthetases for pharmaceutical molecules
A cell-free design-build-test-learn platform generated sequence-function data from 1,217 McbA variants across 10,953 reactions. Ridge-regression ML guided enzyme variants that produced nine small-molecule pharmaceuticals with activity 1.6- to 42-fold above the parent; initial substrate-promiscuity assays found McbA could make 11 pharmaceutical compounds plus hybrid molecules. This is experimental enzyme engineering, not evidence of therapeutic efficacy of the products.
Technology: Augmented ridge-regression ML models within a cell-free sequence-function mapping and enzyme-engineering workflow
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A cell-free design-build-test-learn platform generated sequence-function data from 1,217 McbA variants across 10,953 reactions.
- Still unknown: The platform optimizes in-vitro enzyme production of molecules and does not establish drug efficacy, manufacturing readiness, or broad transferability beyond tested reactions. The nine-product gains are relative to the parent enzyme under the reported assay conditions.
- AI role: Used measured variant fitness data to predict and select higher-activity McbA variants for distinct amide-forming reactions; selected variants were synthesized and assayed.
Evidence sources: https://www.nature.com/articles/s41467-024-55399-0.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 153 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.